Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.
Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.
This podcast episode features Dr. Mark Emberton, a leading expert in interventional oncology, who discusses the ongoing revolution in prostate cancer diagnosis and treatment, moving away from traditional "blind biopsies" towards precision imaging and targeted therapies.
Main Thesis: The most dangerous aspect of prostate cancer may not be the cancer itself, but the historical method of random biopsy. Advanced imaging and focal therapies are transforming prostate care, enabling more accurate diagnosis of clinically significant cancers, reducing unnecessary procedures, and minimizing treatment-related side effects.
Key Points:
WHAT YOU'LL LEARN IN THIS EPISODE:
* Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.
* The difference between "visible" tumors on imaging vs. microscopic disease.
* How PSA density acts as the crucial "tie-breaker" for indeterminate results.
* The future of "See and Treat": Targeting lesions while avoiding surgery side effects.
* Why tumor location (Anterior vs. Posterior) changes your treatment options.
* How AI and new magnets are making MRI screening cheaper and faster.
EPISODE TIMESTAMPS:
00:00 – The dangers of the biopsy needle
02:45 – Innovation in urologic oncology
06:45 – Rising cancer rates in younger men
10:15 – How MRI prevents unnecessary biopsies
12:30 – The PI-RADS "Traffic Light" system
13:45 – PSA Density: The diagnostic tie-breaker
16:30 – Diagnosing without a biopsy
21:00 – AI's role in faster, cheaper MRIs
26:45 – Visible vs. Invisible Cancer: What matters?
35:30 – The "Transform" Study & global screening
42:45 – PSMA PET Scans: Pre-biopsy utility
48:00 – Focal Therapy: Saving the "clockwork"
56:45 – Why tumor location (Anterior) matters
58:30 – Lifestyle and the "Teachable Moment"
01:03:30 – Final advice for patients and policy
Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.
This podcast episode features Dr. Mark Emberton, a leading expert in interventional oncology, who discusses the ongoing revolution in prostate cancer diagnosis and treatment, moving away from traditional "blind biopsies" towards precision imaging and targeted therapies.
Main Thesis: The most dangerous aspect of prostate cancer may not be the cancer itself, but the historical method of random biopsy. Advanced imaging and focal therapies are transforming prostate care, enabling more accurate diagnosis of clinically significant cancers, reducing unnecessary procedures, and minimizing treatment-related side effects.
Key Points:
- Critique of Traditional Biopsies:
- Historically, high PSA led directly to random biopsies, often finding "biological non-events" (low-grade cancers that might never need treatment) and missing aggressive ones.
- Random biopsies carried significant sampling error and trauma, making them unreliable.
- The goal is to significantly reduce the global number of prostate biopsies (from 5-6 million to under 1 million annually).
- The Role of Advanced Imaging in Diagnosis:
- MRI First: Obtaining an MRI before biopsy is crucial. If an MRI is normal (PIRADS 1 or 2), a biopsy can often be avoided.
- PSA Density: This metric, combined with MRI findings, helps refine risk, especially for indeterminate MRI results (PIRADS 3). Low PSA density with a diffuse indeterminate MRI (common in younger men) suggests inflammation rather than significant cancer.
- PSMA PET Scans: When both MRI and PSMA PET scans indicate a positive, localized lesion, the accuracy for identifying clinically significant prostate cancer is extremely high (approaching 100% in some studies). This raises the possibility of proceeding directly to treatment (e.g., surgery) without a prior biopsy, thereby avoiding biopsy-related harms.
- Diagnosis without Biopsy: The ultimate aim is to use advanced imaging to confidently diagnose and stage prostate cancer, potentially eliminating the need for biopsy in many cases, especially when the imaging confirms aggressive, localized disease or rules out significant disease.
- Redefining Prostate Cancer:
- The traditional Gleason grading system for biopsy tissue has evolved and presents challenges for consistent interpretation and research.
- Dr. Emberton proposes a modern definition: a prostate cancer is a lesion that can be seen on imaging.
- Visible cancers have undergone significant genetic and metabolic adaptations (e.g., developing a blood supply, overcoming hypoxia), making them biologically significant. Invisible, microscopic cancers (often Gleason 6) are hypothesized to be transient and unlikely to progress.
- Younger vs. Older Men:
- An increasing number of younger men (40s-50s) are being diagnosed with prostate cancer.
- Traditional PSA thresholds can disadvantage younger men, as PSA naturally rises with age.
- MRI screening (independent of PSA) can detect clinically significant cancers in younger men, even those with "normal" PSA levels (e.g., 1.5 ng/mL).
- Younger men's prostates can be small and compact, sometimes presenting inflammatory changes that might mimic cancer on imaging.
- Future of Diagnosis: AI and Biomarkers:
- AI (Artificial Intelligence): Already used to optimize MRI images and speed up sequences. AI is expected to augment radiologists in interpretation, triage, and burden reduction, though regulatory and liability challenges exist.
- Biomarkers: Companion biomarkers (blood, urine, semen, breath tests) and circulating tumor DNA/cells are under development to further refine diagnostic probabilities and predict aggressiveness.
- UK "Transform" Study: This large study will compare different screening strategies (MRI-first, various PSA thresholds, polygenic risk scores) to determine the most cost-effective approach for detecting clinically significant cancers.
- Future of Treatment: Focal Therapy:
- Early detection of smaller lesions through advanced imaging will lead to significantly fewer radical prostatectomies.
- Focal Therapy: Aims to treat only the cancerous lesion while preserving surrounding healthy tissue, thus minimizing side effects like incontinence and erectile dysfunction, and potentially maintaining ejaculation.
- Energy Sources: Multiple methods exist for destroying tissue (heat, cold, high-voltage electricity, hydro-destruction/aquablation, steam, histotripsy). The specific energy source is less critical than the ability to precisely target and ablate the lesion with adequate margins.
- Lesion Location: Tumors in the anterior (front) part of the prostate are often ideal for focal therapy as they are away from nerves, the urethra, and sphincters. Lesions near the apex or sphincters are more challenging.
- Unanswered Question: The long-term risk of developing new primary cancers in other parts of the prostate after focal therapy remains an area of ongoing study.
- Lifestyle Interventions: Aggressive lifestyle changes (diet, exercise) are critical for patients who undergo focal therapy to reduce the risk of subsequent primary cancers and improve overall health.
WHAT YOU'LL LEARN IN THIS EPISODE:
* Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.
* The difference between "visible" tumors on imaging vs. microscopic disease.
* How PSA density acts as the crucial "tie-breaker" for indeterminate results.
* The future of "See and Treat": Targeting lesions while avoiding surgery side effects.
* Why tumor location (Anterior vs. Posterior) changes your treatment options.
* How AI and new magnets are making MRI screening cheaper and faster.
EPISODE TIMESTAMPS:
00:00 – The dangers of the biopsy needle
02:45 – Innovation in urologic oncology
06:45 – Rising cancer rates in younger men
10:15 – How MRI prevents unnecessary biopsies
12:30 – The PI-RADS "Traffic Light" system
13:45 – PSA Density: The diagnostic tie-breaker
16:30 – Diagnosing without a biopsy
21:00 – AI's role in faster, cheaper MRIs
26:45 – Visible vs. Invisible Cancer: What matters?
35:30 – The "Transform" Study & global screening
42:45 – PSMA PET Scans: Pre-biopsy utility
48:00 – Focal Therapy: Saving the "clockwork"
56:45 – Why tumor location (Anterior) matters
58:30 – Lifestyle and the "Teachable Moment"
01:03:30 – Final advice for patients and policy
Last edited by a moderator:
